PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Press Release
Written by Jamison Wright

https://news.puretechhealth.com/news-releases/news-release-details/puretech-announces-orphan-drug-designations-granted-us-food-and

Jamison Wright https://jamisonwright.com
Previous

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
Next

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis